CG Oncology (CGON) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.90
- Estimate
- -$0.64
- Surprise
- -40.1%
- Revenue (period 2026-06-30)
- $1.2M
- Score today
- 4.9/10
Revenue source: xbrl.
How the report landed
CG Oncology (CGON) reported a wider loss than forecast — diluted EPS of -$0.90 against the -$0.64 estimate (a 40.1% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CGON Sell at 4.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -40.1% surprise compares with a -15.8% four-quarter average. Next scheduled report: 2026-11-09.
What argues against it
- Concentration risk — Pipeline: cretostimogene
- Concentration risk — Supplier: Biovire
- Quality below floor (1.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $72.35
- Price target
- $79.24
- Stop
- $67.90
- Upside to target
- +9.5%
- Reward-to-risk
- 1.2:1
Risk check: RSI 24 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
CGON at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $6.41B
- P/E (fwd)
- -24.0
- 52-week range
- $33.80–$80.97
- Off 52-week high
- 10.6%
- RSI (14)
- 24
- Volume vs avg
- 1.14×
- Score today
- 4.9/10